Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
6.24
+0.13 (2.13%)
Oct 8, 2025, 2:21 PM EDT - Market open
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
66
Market Cap
394.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 316.95K | -1.76M | -84.76% |
| Dec 31, 2021 | 2.08M | -231.57K | -10.02% |
| Dec 31, 2020 | 2.31M | 391.83K | 20.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
IMRX News
- 8 days ago - Immuneering Corporation - Special Call - Seeking Alpha
- 11 days ago - Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 - GlobeNewsWire
- 13 days ago - Immuneering: Positive Pancreatic Cancer Data Atebimetinib Leads To Q4 2025 Catalyst - Seeking Alpha
- 13 days ago - Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi - GlobeNewsWire
- 13 days ago - Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi - GlobeNewsWire
- 13 days ago - Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP - GlobeNewsWire
- 22 days ago - Immuneering Appoints Dr. Thomas Schall as Chairman of the Board - GlobeNewsWire
- 4 weeks ago - Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 - GlobeNewsWire